- Royalty Pharma announced a groundbreaking collaboration with Revolution Medicines providing up to $2 billion in flexible funding.
- Funding includes $1.25 billion synthetic royalty funding and $750 million senior secured debt.
- Agreement designed to offer a new funding paradigm for biotech, allowing companies to retain control of pipeline development.
- First Phase III readout expected in 2026 for pancreatic cancer, with peak potential royalties exceeding $170 million.
- The deal is scale and flexible, with additional funding options based on clinical and sales milestones.
- The partnership is viewed as a blueprint for future innovative funding structures in biotech.
Related items and other data are not available for this feed item.
Dafinchi